Antiviral Drug Discovery To Address the COVID-19 Pandemic | Zendy

Douglas D. Richman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiviral Drug Discovery To Address the COVID-19 Pandemic

Author(s) -

Douglas D. Richman

Publication year - 2020

Publication title -

mbio

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.562

H-Index - 121

eISSN - 2161-2129

pISSN - 2150-7511

DOI - 10.1128/mbio.02134-20

Subject(s) - pandemic , covid-19 , virology , drug discovery , drug , antiviral drug , coronavirus infections , computational biology , biology , medicine , infectious disease (medical specialty) , bioinformatics , virus , pharmacology , disease , outbreak , pathology

The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery and development of effective antiviral drugs for COVID-19 are urgent and should be prioritized. The antiviral drug discovery programs that emerged for HIV and hepatitis C virus have enabled technology and expertise to accelerate this process for SARS-CoV-2. The description of candidate lead inhibitors for the viral main protease (M pro ) exemplifies this accelerated approach and reminds us of the needs and opportunities for addressing this pandemic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research